Cargando…
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288761/ http://dx.doi.org/10.1186/2051-1426-2-S3-P86 |
| _version_ | 1782352019855507456 |
|---|---|
| author | Hurwitz, Herbert Crocenzi, Todd Lohr, Joanna Bonvini, Ezio Johnson, Syd Moore, Paul Wigginton, Jon |
| author_facet | Hurwitz, Herbert Crocenzi, Todd Lohr, Joanna Bonvini, Ezio Johnson, Syd Moore, Paul Wigginton, Jon |
| author_sort | Hurwitz, Herbert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288761 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887612015-01-15 A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma Hurwitz, Herbert Crocenzi, Todd Lohr, Joanna Bonvini, Ezio Johnson, Syd Moore, Paul Wigginton, Jon J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288761/ http://dx.doi.org/10.1186/2051-1426-2-S3-P86 Text en Copyright © 2014 Hurwitz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Hurwitz, Herbert Crocenzi, Todd Lohr, Joanna Bonvini, Ezio Johnson, Syd Moore, Paul Wigginton, Jon A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title | A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title_full | A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title_fullStr | A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title_full_unstemmed | A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title_short | A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| title_sort | phase i, first-in-human, open label, dose escalation study of mgd007, a humanized gpa33 × cd3 dual-affinity re-targeting (dart(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288761/ http://dx.doi.org/10.1186/2051-1426-2-S3-P86 |
| work_keys_str_mv | AT hurwitzherbert aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT crocenzitodd aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT lohrjoanna aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT bonviniezio aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT johnsonsyd aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT moorepaul aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT wiggintonjon aphaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT hurwitzherbert phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT crocenzitodd phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT lohrjoanna phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT bonviniezio phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT johnsonsyd phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT moorepaul phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma AT wiggintonjon phaseifirstinhumanopenlabeldoseescalationstudyofmgd007ahumanizedgpa33cd3dualaffinityretargetingdartproteininpatientswithrelapsedrefractorymetastaticcolorectalcarcinoma |